HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INSILICO

53.900

+0.9001.70%

Volume:17.01M

Turnover:908.45M

Market Cap:31.42B

PE:-12.03

High:55.000

Open:54.350

Low:51.950

Close:53.000

52wk High:80.900

52wk Low:29.980

Shares:583.00M

HK Float Shares:583.00M

Volume Ratio:1.06

T/O Rate:2.92%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-4.480

ROE:--

ROA:-1.36%

PB:7.33

PE(LYR):-12.03

PS:29.66

Loading ...

Overview Company News Filings

Hong Kong Stocks Decline on Renewed U.S.-China Friction; Shenzhen HQVT Technology Shines on Debut

MT Newswires Live

Shaers of Insilico Medicine Jump More Than 15% on SK Biopharmaceuticals Tie-up

THOMSON REUTERS

Insilico Medicine seals AI-driven neuroimmune R&D deal worth up to USD2.50 billion with SK Biopharmaceuticals

Bulletin Express

Insilico Partners with SK Biopharmaceuticals in AI-Powered Neuroscience Drug Discovery Deal Valued Up to $2.5 Billion

BRIEF-Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune Disorders

Insilico Medicine, SK Biopharmaceuticals enter AI drug R&D collaboration worth up to USD 2.5 billion

Insilico Medicine Cayman Topco - and SK Biopharmaceuticals Enter AI-Powered R&D Collaboration Worth up to $2.5 Bln

THOMSON REUTERS

Insilico Medicine Cayman Topco - Total Potential Deal Value Exceeds $2.5 Bln Including Milestones and Royalties

THOMSON REUTERS

Insilico Medicine Cayman Topco - to Receive up to $18 Mln in Upfront and Near-Term Milestone Payments

THOMSON REUTERS

Movement Alert｜Insilico Medicine Falls 5.06% in Regular Trading, Massive Lock-Up Expiry Countdown Suppresses Rebound Momentum

Insilico Shares Surge Nearly 14% on Inclusion in Key China Index Series, Following Multiple Major Index Additions

Insilico Medicine's Stock Surges Over 6% Against Market Trend as Rentosertib Phase 3 Trial Meeting Commences

Movement Alert｜Insilico Medicine Rises 5.05% in Regular Trading, ISM8969 First-in-Human Dosing Milestone Catalyst Extends with Sector Tailwind

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven Nlrp3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration With Hygtia Therapeutics

THOMSON REUTERS

InSilico Medicine Completes First Human Dosing of Parkinson's Disease Drug in Phase 1 Trial

MT Newswires Live

INSILICO Shares Surge Over 6% in Morning Session Following First Patient Dosing Milestone for NLRP3 Inhibitor

Movement Alert｜Insilico Medicine Rises 5.17% in Regular Trading, ISM8969 Achieves First Clinical Milestone with First-in-Human Dosing

Key Hong Kong Market Announcements: Six Firms Launch IPOs, Yum China to Acquire Pizza Hut China for US$1.2 Billion

INSILICO and Hengtai Biotech Achieve First Clinical Milestone for Jointly Developed ISM8969, Dosing Initial Patient in Phase I Study

Insilico Medicine completes first patient dosing in Phase 1 trial of NLRP3 inhibitor ISM8969

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/03696/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"03696","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03696\",,,,,undefined,":{"symbol":"03696","market":"HK","secType":"STK","nameCN":"INSILICO","latestPrice":53.9,"timestamp":1789027724005,"preClose":53,"halted":0,"volume":17013805,"delay":0,"changeRate":0.01698113207547167,"floatShares":583000000,"shares":583000000,"eps":-4.48,"marketStatus":"Not Yet Opened","change":0.9,"latestTime":"09-10 16:08:44","open":54.35,"high":55,"low":51.95,"amount":908453357,"amplitude":0.057547,"askPrice":53.95,"askSize":2000,"bidPrice":53.9,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-4.006,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1767024000000,"exchange":"SEHK","adjPreClose":53,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":1.06069,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03696\",,,,,undefined,":{"symbol":"03696","floatShares":583000000,"roa":"-1.36%","roe":"--","lyrEps":-4.48,"volumeRatio":1.06069,"shares":583000000,"dividePrice":0,"high":55,"amplitude":0.057547,"preClose":53,"low":51.95,"week52Low":29.98,"pbRate":"7.33","psRate":"29.66","week52High":80.9,"institutionHeld":0,"latestPrice":53.9,"committee":0.428571,"eps":-4.48,"divideRate":0,"volume":17013805,"delay":0,"ttmEps":-4.006,"open":54.35,"prevYearClose":37.14,"prevWeekClose":48.76,"prevMonthClose":43.74,"prevQuarterClose":39.62,"fiveDayClose":47,"twentyDayClose":46.38,"sixtyDayClose":32.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03696\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"03696","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"03696","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03696\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03696\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1786032000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/03696\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"03696","date":"2026-09-09","current":-13.354968,"percent":0.435294,"low":-126.474328,"twenty":-93.127559,"median":-12.517861,"eighty":-8.791356,"high":-6.819055,"avg":-40.471792,"sd":41.550192,"marketCap":30519413046},"quantilePoints":[{"date":"2026-01-02","current":-60.518922,"twenty":-60.091977,"median":-54.070713,"eighty":-44.509914,"marketCap":20885577298},{"date":"2026-01-09","current":-75.603624,"twenty":-68.00457,"median":-60.518922,"eighty":-55.21804,"marketCap":26120865700},{"date":"2026-01-16","current":-88.730045,"twenty":-88.029114,"median":-68.708073,"eighty":-60.032461,"marketCap":30678123120},{"date":"2026-01-23","current":-103.197987,"twenty":-90.498742,"median":-83.671368,"eighty":-60.384368,"marketCap":35679909160},{"date":"2026-01-30","current":-103.586135,"twenty":-97.608242,"median":-87.528966,"eighty":-61.04227,"marketCap":35850899140},{"date":"2026-02-06","current":-102.242154,"twenty":-102.624487,"median":-88.730045,"eighty":-63.670801,"marketCap":35423424190},{"date":"2026-02-13","current":-120.862692,"twenty":-111.02361,"median":-93.674734,"eighty":-69.411577,"marketCap":41892545100},{"date":"2026-02-20","current":-120.573146,"twenty":-113.535701,"median":-95.532684,"eighty":-72.22559,"marketCap":41778551780},{"date":"2026-02-27","current":-101.790811,"twenty":-112.276672,"median":-99.165731,"eighty":-75.603624,"marketCap":35309430870},{"date":"2026-03-06","current":-91.269503,"twenty":-111.865913,"median":-96.698006,"eighty":-83.671368,"marketCap":31633146300},{"date":"2026-03-13","current":-90.695168,"twenty":-110.462075,"median":-97.855611,"eighty":-84.923636,"marketCap":31476674990},{"date":"2026-03-20","current":-90.217416,"twenty":-108.336494,"median":-95.132264,"eighty":-85.637602,"marketCap":31333988340},{"date":"2026-03-27","current":-94.081335,"twenty":-107.867915,"median":-93.382526,"eighty":-84.923636,"marketCap":32646705520},{"date":"2026-04-02","current":-11.868567,"twenty":-107.743793,"median":-93.151788,"eighty":-79.84609,"marketCap":32770014500},{"date":"2026-04-10","current":-12.877757,"twenty":-106.637664,"median":-92.691879,"eighty":-68.00457,"marketCap":35546164200},{"date":"2026-04-17","current":-12.624497,"twenty":-104.449464,"median":-91.076584,"eighty":-59.957423,"marketCap":34802041600},{"date":"2026-04-24","current":-14.676127,"twenty":-103.459526,"median":-89.747522,"eighty":-15.148699,"marketCap":40497441500},{"date":"2026-04-30","current":-13.071473,"twenty":-103.255287,"median":-88.68986,"eighty":-14.223075,"marketCap":36089946100},{"date":"2026-05-08","current":-13.340785,"twenty":-103.091175,"median":-88.574112,"eighty":-13.384736,"marketCap":36805448600},{"date":"2026-05-15","current":-10.983422,"twenty":-102.596106,"median":-86.723486,"eighty":-13.331626,"marketCap":30308685900},{"date":"2026-05-22","current":-10.451313,"twenty":-102.308283,"median":-85.637602,"eighty":-12.881328,"marketCap":28849060800},{"date":"2026-05-29","current":-8.622113,"twenty":-102.242154,"median":-83.671368,"eighty":-12.624497,"marketCap":23800475160},{"date":"2026-06-05","current":-7.875348,"twenty":-101.790811,"median":-78.255166,"eighty":-12.515704,"marketCap":21739827960},{"date":"2026-06-12","current":-7.01543,"twenty":-100.06892,"median":-65.190557,"eighty":-12.085532,"marketCap":19370083680},{"date":"2026-06-18","current":-7.947724,"twenty":-100.046598,"median":-60.518922,"eighty":-10.958896,"marketCap":21945892680},{"date":"2026-06-26","current":-7.919554,"twenty":-99.340788,"median":-54.070713,"eighty":-10.005367,"marketCap":21877204440},{"date":"2026-07-03","current":-7.743582,"twenty":-98.690073,"median":-27.191152,"eighty":-9.565807,"marketCap":21396386760},{"date":"2026-07-10","current":-8.877372,"twenty":-98.062553,"median":-14.676127,"eighty":-8.824583,"marketCap":24510253640},{"date":"2026-07-17","current":-8.953114,"twenty":-97.4013,"median":-14.167396,"eighty":-8.882012,"marketCap":24727766400},{"date":"2026-07-24","current":-9.751189,"twenty":-96.617922,"median":-13.560542,"eighty":-8.925911,"marketCap":26937238120},{"date":"2026-07-31","current":-9.466525,"twenty":-95.411086,"median":-13.340785,"eighty":-8.88656,"marketCap":26158771400},{"date":"2026-08-07","current":-9.410567,"twenty":-94.035578,"median":-13.201047,"eighty":-8.763781,"marketCap":26009946880},{"date":"2026-08-14","current":-9.225945,"twenty":-93.733176,"median":-12.895614,"eighty":-8.825762,"marketCap":25506233120},{"date":"2026-08-21","current":-8.414722,"twenty":-93.349385,"median":-12.788902,"eighty":-8.725669,"marketCap":23250969240},{"date":"2026-08-28","current":-11.42993,"twenty":-93.240519,"median":-12.603589,"eighty":-8.725669,"marketCap":26661298566},{"date":"2026-09-04","current":-12.035257,"twenty":-93.142096,"median":-12.516782,"eighty":-8.763781,"marketCap":28077860002},{"date":"2026-09-09","current":-13.078998,"twenty":-93.127559,"median":-12.517861,"eighty":-8.791356,"marketCap":30519413046}],"updateTime":1789027304168},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03696\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645474480","title":"Hong Kong Stocks Decline on Renewed U.S.-China Friction; Shenzhen HQVT Technology Shines on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2645474480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645474480?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:31","pubTimestamp":1782117099,"startTime":"0","endTime":"0","summary":"Hong Kong stocks fell on Monday as investors reacted to unchanged Chinese lending rates and renewed U.S.-China tensions after Beijing imposed export controls on several American entities.The Hang Seng","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02800","HSTECH","09115","07300","513600","02833","82800","HHImain","HSI","07200","MHImain","03696","MCHmain","03115","83115","03419","BK1141","07500","03037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645046043","title":"Shaers of Insilico Medicine  Jump More Than 15% on SK Biopharmaceuticals Tie-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2645046043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645046043?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:17","pubTimestamp":1782109065,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160977156","title":"Insilico Medicine seals AI-driven neuroimmune R&D deal worth up to USD2.50 billion with SK Biopharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=1160977156","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160977156?lang=en_us&edition=fundamental","pubTime":"2026-06-22 13:03","pubTimestamp":1782104626,"startTime":"0","endTime":"0","summary":"Insilico Medicine Cayman TopCo (Insilico Medicine) has entered a research and development collaboration with SK Biopharmaceuticals Co., Ltd. aimed at discovering artificial-intelligence-enabled drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151101147","title":"Insilico Partners with SK Biopharmaceuticals in AI-Powered Neuroscience Drug Discovery Deal Valued Up to $2.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1151101147","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151101147?lang=en_us&edition=fundamental","pubTime":"2026-06-22 13:00","pubTimestamp":1782104421,"startTime":"0","endTime":"0","summary":"In a significant development, Insilico (03696) has announced the formation of a research collaboration with SK Biopharmaceuticals (SK Biopharmaceuticals). The partnership is focused on discovering...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","CHAT","AGIX","03696","SK","ARTY","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645437070","title":"BRIEF-Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2645437070","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645437070?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:41","pubTimestamp":1782103319,"startTime":"0","endTime":"0","summary":"BRIEF-Insilico Medicine And SK Biopharmaceuticals Collaborate On Drug Discovery For Neuroimmune DisordersJune 22 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:INSILICO MEDICINE AND SK BIOPHARMACE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUABLJMR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645043422","title":"Insilico Medicine, SK Biopharmaceuticals enter AI drug R&D collaboration worth up to USD 2.5 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2645043422","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645043422?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:26","pubTimestamp":1782102384,"startTime":"0","endTime":"0","summary":"Insilico Medicine Cayman Topco entered an AI-driven drug discovery collaboration with SK Biopharmaceuticals focused on neuroimmune disorders in the central nervous system.Insilico will use its Pharma.AI platform to discover and optimize candidates; SK Biopharmaceuticals will lead late-stage development, clinical work, and commercialization.Insilico is eligible for up to USD 18 million in upfront and near-term milestones.Total potential value exceeds USD 2.5 billion, including development, regulatory, commercial milestones, and single-digit royalties on net sales.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6srZ0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645604342","title":"Insilico Medicine Cayman Topco - and SK Biopharmaceuticals Enter AI-Powered R&D Collaboration Worth up to $2.5 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2645604342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645604342?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:26","pubTimestamp":1782102375,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S017:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645043429","title":"Insilico Medicine Cayman Topco - Total Potential Deal Value Exceeds $2.5 Bln Including Milestones and Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2645043429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645043429?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:26","pubTimestamp":1782102375,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S017:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645043421","title":"Insilico Medicine Cayman Topco - to Receive up to $18 Mln in Upfront and Near-Term Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2645043421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645043421?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:26","pubTimestamp":1782102375,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S017:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111843548","title":"Movement Alert｜Insilico Medicine Falls 5.06% in Regular Trading, Massive Lock-Up Expiry Countdown Suppresses Rebound Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1111843548","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111843548?lang=en_us&edition=fundamental","pubTime":"2026-06-22 11:28","pubTimestamp":1782098896,"startTime":"0","endTime":"0","summary":"On June 22, Insilico Medicine fell 5.06% in regular trading, trading at HK$36.5/share, with turnover of HK$125 million.On the news front, despite the company being formally included in the FTSE...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155526283","title":"Insilico Shares Surge Nearly 14% on Inclusion in Key China Index Series, Following Multiple Major Index Additions","url":"https://stock-news.laohu8.com/highlight/detail?id=1155526283","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155526283?lang=en_us&edition=fundamental","pubTime":"2026-06-18 16:21","pubTimestamp":1781770884,"startTime":"0","endTime":"0","summary":"Shares of Insilico (03696) rose strongly against the broader market trend throughout the trading session. By the close, the stock had gained 13.84% to HK$38.34, with a turnover of HK$338 million.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","BK4588","VXUS","BK4585","03696","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102796039","title":"Insilico Medicine's Stock Surges Over 6% Against Market Trend as Rentosertib Phase 3 Trial Meeting Commences","url":"https://stock-news.laohu8.com/highlight/detail?id=1102796039","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102796039?lang=en_us&edition=fundamental","pubTime":"2026-06-18 10:34","pubTimestamp":1781750070,"startTime":"0","endTime":"0","summary":"Shares of Insilico Medicine (03696) rose more than 6% against the broader market trend. At the time of writing, the stock was up 6.65% to HK$35.92, with a turnover of HK$48.60 million. The catalyst...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","CHAT","BK1141","BK4588","03696","AIPO","AGIX","BK4585","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113078048","title":"Movement Alert｜Insilico Medicine Rises 5.05% in Regular Trading, ISM8969 First-in-Human Dosing Milestone Catalyst Extends with Sector Tailwind","url":"https://stock-news.laohu8.com/highlight/detail?id=1113078048","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113078048?lang=en_us&edition=fundamental","pubTime":"2026-06-18 10:12","pubTimestamp":1781748765,"startTime":"0","endTime":"0","summary":"On June 18, Insilico Medicine rose 5.05% in regular trading, trading at HK$35.08/share, with turnover of HK$34.16 million.On the news front, the rally extends the positive momentum from the previous...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749844","title":"Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven Nlrp3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration With Hygtia Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749844","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644749844?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:00","pubTimestamp":1781701204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA7DC6R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644413718","title":"InSilico Medicine Completes First Human Dosing of Parkinson's Disease Drug in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644413718","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644413718?lang=en_us&edition=fundamental","pubTime":"2026-06-17 13:52","pubTimestamp":1781675530,"startTime":"0","endTime":"0","summary":"InSilico Medicine Cayman  completed first-in-human dosing in a phase 1 clinical trial of ISM8969, according to a Wednesday Hong Kong bourse filing.The oral NLRP3 inhibitor is being developed to treat chronic neuroinflammation and central nervous system disorders, including Parkinson's disease.The milestone marks the first clinical achievement under the company's co-development collaboration with Hygtia Therapeutics.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["03696","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199395994","title":"INSILICO Shares Surge Over 6% in Morning Session Following First Patient Dosing Milestone for NLRP3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1199395994","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199395994?lang=en_us&edition=fundamental","pubTime":"2026-06-17 10:14","pubTimestamp":1781662465,"startTime":"0","endTime":"0","summary":"Shares of INSILCO (03696) rose more than 6% during the morning trading session. At the time of writing, the stock was up 4.93% to HK$34.5, with a turnover of HK$21.1158 million. Key Development The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK1141","03696","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103060181","title":"Movement Alert｜Insilico Medicine Rises 5.17% in Regular Trading, ISM8969 Achieves First Clinical Milestone with First-in-Human Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=1103060181","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103060181?lang=en_us&edition=fundamental","pubTime":"2026-06-17 09:58","pubTimestamp":1781661503,"startTime":"0","endTime":"0","summary":"On June 17, Insilico Medicine rose 5.17% in regular trading, trading at 34.62 HKD/share, with turnover of approximately 13.92 million HKD.On the news front, the company announced that ISM8969,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150986317","title":"Key Hong Kong Market Announcements: Six Firms Launch IPOs, Yum China to Acquire Pizza Hut China for US$1.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1150986317","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150986317?lang=en_us&edition=fundamental","pubTime":"2026-06-17 09:26","pubTimestamp":1781659607,"startTime":"0","endTime":"0","summary":"Several new listings are commencing their public offerings in Hong Kong. Lingyi Itech(Guangdong)Company (HKEX: 01688) has initiated its share offering today, with cornerstone investors including GF...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK1144","002600","HK0000306701.USD","IPOS","LU1023057109.AUD","LU0543330483.HKD","LU0029875118.USD","HK0000320264.USD","LU0128522157.USD","BK4504","BK0077","BK0028","LU0359202008.SGD","LU0823426308.USD","LU0708994859.HKD","BK1588","HK0000306685.HKD","LU0672654166.SGD","VXUS","09987","IE00B0JY6N72.USD","YUMC","LU2008162690.USD","LU0456842615.SGD","BK4585","LU0128525929.USD","IE0034224299.USD","LU2177674079.SGD","BK0084","LU0572944931.SGD","LU0310800379.SGD","IE0003895053.USD","BK1617","HK0000320223.HKD","BK4531","LU0651946864.USD","LU1051768304.USD","BK0251","BK1141","02252","IE00BGV7N243.SGD","LU1267930573.SGD","LU0359201612.USD","LU0650527681.SGD","BK0132","LU1515016050.SGD","LU0228659784.USD","LU0868486357.SGD","LU0823426480.USD","BK4209","BK4588","LU0594300419.USD","LU0348825331.USD","LU0327786744.USD","BK1233","02889","06675","BK4526","LU0431992006.USD","688630","LU2279701549.SGD","LU0417516902.SGD","BK0214","LU0029864427.USD","BK1100","BK0081","LU0320764755.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145575282","title":"INSILICO and Hengtai Biotech Achieve First Clinical Milestone for Jointly Developed ISM8969, Dosing Initial Patient in Phase I Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1145575282","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145575282?lang=en_us&edition=fundamental","pubTime":"2026-06-17 08:36","pubTimestamp":1781656586,"startTime":"0","endTime":"0","summary":"INSILICO (03696) announced that ISM8969, co-developed with Shenzhen Hengtai Biotechnology Co., Ltd. (Hengtai Biotech), has reached its first clinical milestone with the administration of the first...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644679699","title":"Insilico Medicine completes first patient dosing in Phase 1 trial of NLRP3 inhibitor ISM8969","url":"https://stock-news.laohu8.com/highlight/detail?id=2644679699","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644679699?lang=en_us&edition=fundamental","pubTime":"2026-06-17 08:00","pubTimestamp":1781654440,"startTime":"0","endTime":"0","summary":"Insilico Medicine Cayman Topco dosed the first participant in a Phase 1 study of ISM8969, an oral NLRP3 inhibitor developed with HengTai Bio.No clinical results have been presented; the announcement covers trial initiation and first-in-human dosing.The study is designed to assess safety and tolerability in healthy volunteers and obese adults with cardiovascular risk.Insilico granted HengTai Bio global rights to develop and commercialize ISM8969; the partners split worldwide economics 50%-50%.The deal includes up to USD 66 million in upfront and milestone payments to Insilico.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL76jGx7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}